Compare MIRM & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | FCN |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.6B |
| IPO Year | 2019 | 1996 |
| Metric | MIRM | FCN |
|---|---|---|
| Price | $107.23 | $145.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 1 |
| Target Price | $119.85 | ★ $165.00 |
| AVG Volume (30 Days) | ★ 637.7K | 412.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 5.51 |
| EPS | N/A | ★ 1.90 |
| Revenue | $19,138,000.00 | ★ $3,788,857,000.00 |
| Revenue This Year | $26.22 | $7.39 |
| Revenue Next Year | $22.04 | $7.10 |
| P/E Ratio | ★ N/A | $76.13 |
| Revenue Growth | N/A | ★ 2.44 |
| 52 Week Low | $47.89 | $140.84 |
| 52 Week High | $114.99 | $189.30 |
| Indicator | MIRM | FCN |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 32.68 |
| Support Level | $87.93 | $140.84 |
| Resistance Level | $107.51 | $165.56 |
| Average True Range (ATR) | 4.13 | 5.21 |
| MACD | 1.17 | -0.29 |
| Stochastic Oscillator | 96.61 | 18.39 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.